Capricor Therapeutics (CAPR) Receives $4.2M NIH Grant for CAP-2003 Development in HLHS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- S&P, Nasdaq muted as bond yields rise; UnitedHealth boosts Dow
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- BofA profit hurt by provisions even as it expects rising interest income
- Morgan Stanley (MS) earnings beat lifts stock
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
Capricor Therapeutics Awarded Up to $4.2 Million from National Institutes of Health to Evaluate Exosomes for Hypoplastic Left Heart Syndrome
October 20, 2016 7:00 AM EDTLOS ANGELES, Oct. 20, 2016 /PRNewswire/ --Â Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing biological therapies for cardiac and other serious medical conditions, today announced that it has been awarded a grant of up to $4.2 million from the National Institutes of Health to study CAP-2003 (cardiosphere-derived cell exosomes) for hypoplastic left heart syndrome (HLHS).
"Capricor's successful record of competing for non-dilutive sources of capital reflects our commitment to scientific excellence as well as the importance of... More
